Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6028243

Title:Mice and cells with a homozygous disruption in the RNase L gene and methods therefore
Inventors:Silverman, Robert H.; Beachwood, OH, USA
Zhou, Aimin; Solon, OH, USA
Summary:This invention introduces a novel mutant nonhuman mammal with a homozygous disruption of the RNase L gene. Described herein is a mutant mouse with a homozygous disruption in the RNase L gene which causes minimal production of RNase L, such that the mouse exhibits a reduced response to interferon-alpha treatment following encephalomyocarditis viral infection when compared to wild-type mice. Claims of the invention include uses of such mutant mice in the assessment of the effects of antiviral drugs on the induction, synthesis, or activation of RNase L. Further provided are embryonic stem cell lines having a heterozygous disruption of the RNase L gene and a DNA construct comprising a DNA sequence of a disrupted coding exon of the RNase L gene. Experimental applications include the use of such a mutant mouse in the assessment of the 2-5 synthase system in the antiviral effect of various agents.
Abstract:The present invention provides a mutant, non-human mammal, particularly a mutant mouse, having a homozygous disruption in the RNase L gene thereof. Since the homozygous disruption in the RNase L gene leads to minimal if any production of RNase L in the mutant mammals, such mutant mammals are useful for assessing the effect of antiviral drugs on the induction, synthesis, or activation of RNase L. The present invention also relates to mutant, non-human, embryonic stem cell lines having a heterozygous disruption of the RNase L gene thereof, to isolated mammalian cells having a homozygous disruption in the RNase L gene thereof, and to a DNA construct comprising a DNA sequence of a disrupted coding exon of a RNase L gene.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6028243
Application Number:US1997000943956
Date Filed:03/10/1997
Date Published:22/02/2000
Assignee:The Cleveland Clinic Foundation, Cleveland, OH, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/5/2020